MicroRNAs as possible cypplin-induced nephrotoxicity predictors in head and neck cancer patients

• Grant number: 19/20010-7
• Support Opportunities: Scholarships in Brazil - Master
• Start date: June 01, 2020
• End date: May 31, 2022
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Patricia Moriel
• Grantee: Nadine de Godoy Torso
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated scholarship(s): 21/08205-7 - Evaluation of the role of miRNAs related to cysplatin-induced nephrotoxicity in vitro, BE.EP.MS

Abstract

Head and neck cancer corresponds to tumors located in the upper aerodigestive tract. The most effective treatment is radiotherapy concomitant with chemotherapy with high doses of cisplatin; however, its use is limited due to its adverse reactions, especially nephrotoxicity. Therefore, there is a need for identification of nephrotoxicity predictor molecules, since classical pathological markers have low sensitivity and specificity. Among the proposed biomarkers in recent years, one of the most promising is miRNA. The aim of this study will be to evaluate miRNAs as possible predictors of cisplatin-induced nephrotoxicity in head and neck cancer patients. This is an analytical, experimental, clinical, single-arm, prospective and quantitative study, whose sampling was non-probabilistic consecutive. Patients with head and neck cancer who underwent antineoplastic treatment with cisplatin (80-100mg/m2 every 21 days for 3 cycles; only the 1st cycle being considered) with concurrent radiotherapy will be included. Nephrotoxicity, gastrointestinal toxicities and myelotoxicity will be assessed for severity according to CTCAE v5. The expression of plasma miRNAs in relation to cisplatin-induced nephrotoxicity will be evaluated to find a correlation that makes them predictive molecules of this toxicity. Statistical analysis will be performed using the Chiquadrado, Fisher exact, Mann-Whitney and ANOVA tests for repeated measures, considering p <0.05 as significant. (AU)

Scientific publications

(4)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE GODOY TORSO, NADINE; VISACRI, MARILIA BERLOFA; QUINTANILHA, JULIA COELHO FRANCA; CURSINO, MARIA APARECIDA; PINCINATO, EDER DE CARVALHO; MORIEL, PATRICIA. Assessment of Renal Function in Head and Neck Cancer Patients Treated with Cisplatin: Different Biomarkers and Acute Kidney Injury Classifications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v. 24, n. 1, p. 18-pg., 2023-01-01. (19/20010-7, 17/17245-7, 17/02338-0)

VASCONCELOS, PEDRO E. N. S.; VISACRI, MARILIA B.; PINCINATO, EDER DE C.; TORSO, NADINE DE G.; SEGUIN, CECILIA S.; ZAMBON, LAIR; BARBEIRO, ARISTOTELES DE S.; MAURICIO, W. P. JUNIOR; MORIEL, PATRICIA. miRNAs as biomarkers of adverse drug reactions to platinum-based agents in patients with non-small-cell lung cancer. BIOMARKERS IN MEDICINE, v. 15, n. 13, p. 4-pg., 2021-08-17. (19/20010-7, 19/13250-1)

TORSO, N. D. G.; QUINTANILHA, J. C. F.; CURSINO, M. A.; BORGES, J. B.; PINCINATO, E. D. C.; LIMA, C. S. P.; NAVARRETE, L. A. S.; MORIEL, P.. Urinary MicroRNAs as Possible Biomarkers of Cisplatin-Induced Nephrotoxicity in Patients with Head and Neck Cancer. DRUG SAFETY, v. 45, n. 10, p. 2-pg., 2022-10-01. (19/20010-7, 19/13250-1)

TORSO, NADINE DE GODOY; QUINTANILHA, JULIA COELHO FRANCA; CURSINO, MARIA APARECIDA; PINCINATO, EDER DE CARVALHO; LIMA, CARMEN SILVIA PASSOS; MORIEL, PATRICIA. Data Normalization of Urine miRNA Profiling from Head and Neck Cancer Patients Treated with Cisplatin. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v. 24, n. 13, p. 15-pg., 2023-07-01. (19/20010-7, 17/02338-0, 19/13250-1)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

TORSO, Nadine de Godoy. MicroRNAs as possible biomarkers of cisplatin-induced nephrotoxicity in patients with head and neck cancer. 2022. Master's Dissertation - Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas Campinas, SP.